A novel radionuclide drug tackles the
challenge of prostate cancer imaging and takes a turn as a
cancer-killing therapy for tumors in and out of the prostate, according
to research presented during the 2015 Annual Meeting of the Society of
Nuclear Medicine and Molecular Imaging (SNMMI).
"Prostate cancer still represents one of the main causes for
cancer-related deaths among men," said Matthias Eder, PhD, co-author of
the study and a researcher in the division of radiopharmaceutical
chemistry at the German Cancer Research Center in Heidelberg, Germany.
"The diagnosis and therapy of metastatic prostate cancer
is still challenging. The current clinical methods are not sensitive
enough for detecting disease beyond the prostate, but we are convinced
that this novel theranostic radiotracer represents a significant step
forward that could have a major impact on the future of prostate cancer
care."
The PSMA-inhibiting theranostic agent, called PSMA-617, is still in
its initial stages, but it could be ideal for the treatment of patients
with hormone-refractory prostate cancers, which are notoriously
difficult to control and linked to poor prognosis. Options for these
patients are few, and they come with substantial adverse effects.
Diagnosis and therapy with the theranostic agent PSMA-617 could offer
more effective and sensitive visualization, better staging and
significantly higher therapeutic potential.
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment